Mrs. Kelly Kubala Mehan, L.C.S.W Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 408 Jefferson Street, St. Charles, MO 63301 Phone: 314-440-5800 |
Stephanie Holdmeier, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 408 Jefferson St, St. Charles, MO 63301 Phone: 636-856-4847 |
Betsy W Schlueter-brannam, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 14 Eagle Crest Ln, St. Charles, MO 63303 Phone: 314-313-0898 |
News Archive
The virtual Iraq simulation, developed at the University of Southern California (USC) but now being put into practice at Reading, is "fully-immersive" and designed as part of an exposure therapy programme which allows soldiers suffering post-traumatic stress disorder to relive and confront psychological trauma - and it has produced promising results for the first handful of patients treated.
Advertisers and public health officials may be able to access hidden wisdom in the brain to more effectively sell their products and promote health and safety, UCLA neuroscientists report in the first study to use brain data to predict how large populations will respond to advertisements.
Nordion Inc., a leading provider of products and services to the global health science market, announced that it has entered into a definitive agreement (the "Arrangement Agreement") to be acquired by Sterigenics, a global leader in sterilization services and a portfolio company of GTCR LLC, a leading private equity firm based in Chicago, Illinois, USA.
Facing rising penalties under the health-care law for high readmission rates, some hospitals are turning to tech entrepreneurs like Chris Corio of San Francisco for help. Mr. Corio's four-year-old startup sells technology that assists patients in completing the recovery process after getting discharged.
Alexza Pharmaceuticals, Inc. announced today that it has established a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, to develop and commercialize AZ-004 (Staccato® loxapine) in the U.S. and Canada. AZ-004 is Alexza's lead program, based on the company's proprietary technology, the Staccato system. Alexza submitted its New Drug Application (NDA) for Staccato loxapine in December 2009. Alexza is seeking regulatory approval to market AZ-004, an inhalation product candidate developed for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder.
› Verified 6 days ago